Background: Multiplex ligation-dependent probe amplification (MLPA) is a polymerase chain reaction-based assay that can assess HER2 gene copy number relative to control genes.
A s the amplification status of the HER2 gene impacts management options for women with breast cancer, current recommendations of the American Society of Clinical Oncology (ASCO) Tumor Marker Guidelines Panel include routine testing of HER2 on all newly diagnosed and metastatic invasive breast cancers for the purpose of guiding selection of traztuzumab therapy. 1 The choice of assays has included immunohistochemistry (IHC) to detect protein overexpression and in situ hybridization (ISH) to determine gene amplification.
In 2007, on the basis of a systematic review of the literature, the ASCO and the College of American Pathologists (CAP) jointly proposed guidelines for HER2 testing. 2 The panel noted significant discordance between the results reported by local laboratories and central testing, ranging 74-81.6% for IHC and between 67%-88.1% for FISH. These discordances included false-positive and false-negative cases. The panel emphasized the need for accurate, reproducible assay performance, including newly available types of bright field ISH. They made recommendations with regard to test validation and quality assurance and proposed criteria for the ISH testing of HER2.
ALTERNATIVE TESTING PLATFORMS FOR HER2
Chromogenic in situ hybridization (CISH) is an ISHbased assay that is carried out with bright field microscopy. The technique has been validated against IHC and FISH. 3 As HER2 gene amplification predicts response to traztuzumab therapy, quantitative real-time polymerase chain reaction (Q-PCR) techniques are, in theory, applicable for making this determination. However, to date, studies have shown only moderate concordance with IHC and ISH techniques. [4] [5] [6] [7] Mulitplex ligation-dependent probe amplification (MLPA) is a PCR-based technique that uses multiple probes directed against both the target gene(s) and control genes in each PCR, enabling the calculation of HER2 copy number relative to the copy number of multiple control genes on chromosome 17 and other chromosomes under the same test conditions. 8 Since its introduction in 2002, MLPA has gained widespread clinical acceptance for the identification of gene copy number changes in a broad range of predominantly genetic diseases, including cancer predisposition syndromes, mental retardation, muscular dystrophy, cystic fibrosis, the identification of aneuploidy and trisomies, and more recently for HER2 amplification. [9] [10] [11] MLPA is highly suited for the analysis of fragmented DNA found in formalin-fixed, paraffin-embedded (FFPE) tissues, as it requires only short sequences of target DNA for the gene-specific MLPA probe to bind.
MLPA uses pairs of probes for each DNA sequence of interest that are designed to hybridize immediately adjacent to each other. When this happens the 2 probes can be ligated by a DNA ligase, ensuring high fidelity of the assessment. Each MLPA probe contains a genespecific sequence and a common PCR primer sequence, which can be amplified only if the probe pair is successfully ligated. In addition, each MLPA probe pair contains nonspecific spacer sequences that can be used to distinguish each probe pair by its length when analyzed on a DNA sequencer. Each MLPA assay can evaluate up to 45 different target DNA sequences in a single reaction, each probe being directed at a different unique hybridization sequence. 8 Once the different length fragments are separated on the sequencer, they are quantitated by the amount of fluorescence detected in each fragment. The ratio of the fluorescence signal of the gene target of interest to the control gene segments allows simple and accurate quantitation of the target sequence of interest.
A probe set for the measurement of HER2 gene amplification is available commercially (P004-A1 HER2 kit MRC Holland, Amsterdam, the Netherlands www.mrcholland.com). This probe set includes three probes for HER2, each directed specifically at a different segment of the gene. There are also 11 probes for other genes located on chromosome 17. Furthermore, the kit includes 25 control probes for genes on other chromosomes.
Two small earlier studies evaluated the use of MLPA for the measurement of HER2 gene amplification in breast cancer. Moerland 
MATERIALS AND METHODS

Study Design
In Australia, government subsidy for access to traztuzumab is contingent on the demonstration of HER2 amplification by ISH. At our laboratory, bright field ISH is the first-line assay for the determination of HER2 status of all newly diagnosed breast cancers. The laboratory has undergone accreditation to provide this service by satisfying stringent accreditation and regulatory requirements with regard to equipment, procedures, and competency of technical and pathology personnel. CISH was used for HER2 assessment for this study. Criteria for reporting of single probe CISH results are based on the ASCO/CAP guidelines and adopted by the Australian HER2 Testing Advisory Board, as shown in Table 1 .
Tumors
Institutional ethics approval was obtained for this study. Between January and October 2007, 208 consecutive invasive breast cancers undergoing diagnostic CISH testing in our laboratory were also tested with MLPA for this validation study.
All tests were performed on routine FFPE tissue samples of invasive breast cancers. Consecutive sections of were cut for CISH (5 mm), MLPA (10 mm), and FISH (5 mm) testing. CISH was carried out according to the manufacturer's instructions using the Zymed CISH kit (84-0146) and the Invitrogen Spotlight detection system. The HER2 signals were counted in at least 30 tumor cells and the average signal number per cell was calculated. A CEP17 probe was not used routinely. The results were reported as per ASCO/CAP guidelines for single-probe systems. contractual arrangements, by a central accredited FISH laboratory. Additional FISH was undertaken in-house on selected cases for this study, mainly in those suspected to show polysomy, but also cases for which no signal had been observed in the initial FISH assay, or for confirmation of results.
MLPA
Tumor tissue for each sample was isolated by macrodissection. For this, the pathologist marked a representative area of invasive tumor on one hematoxylin and eosin (H&E)-stained slide. The most cellular regions with the least amount of DCIS or stroma were selected. An adjacent unstained slide, cut at 10 mm, was used for MLPA assessment. This was de-waxed and rehydrated. The area of tumor was marked on the unstained slide by comparison with the marked H&E slide. The tumor tissue was removed from this slide by covering the designated area with water and scraping the tissue with a clean pipette tip to resuspend the tissue (Fig. 1 ). This was then transferred to a DNasefree tube and dried, using a vacuum centrifuge. DNA was extracted using the QIAamp DNA Mini kit (Qiagen, www.qiagen.com) according to the tissue protocol, with digestion by overnight incubation and DNA elution in 30 mL AE buffer.
The HER2-neu MLPA kit (P004) from MRC Holland was used for the test, which was performed according to the manufacturer's instructions. Approximately 50 ng of DNA was used for each reaction. The samples were run on a 3730 DNA sequencer (Applied Biosystems, Foster City, CA) using ROX 500 as the size marker. Results were analyzed using Gene Mapper v 4.0 software (Applied Biosystems) to calculate the peak area corresponding to each probe.
DNA prepared from 5 breast tumor samples earlier confirmed to have normal expression levels of HER2 was run as a control with each MLPA assay. For each run these results were averaged to provide the normal control against which the samples were compared.
To minimize differences caused by experimental variation, all peak areas were normalized by dividing the individual peak area by the total area of all the peaks for that sample. 15 A dosage ratio was then determined for each probe by comparing the normalized peak area with the corresponding normalized peak area of the normal control. A ratio-based approach such as this gives a normal value of one; therefore, to calculate a gene copy number the result was multiplied by 2, allowing easy comparison with CISH and IHC results. The MLPA kit contains 3 probes directed toward the HER2 gene. The results for the 3 probes were averaged and a patient was considered to have amplification of the HER2 gene if this gave a result of greater than 4 copies.
HER2-amplified cell line SKBR3, known to overexpress HER2, with normal DNA.
The reproducibility of the MLPA assay was assessed and established using DNA prepared from 2 breast cancer cell lines, SKBR3 cells that are known to overexpress HER2, and MDAMB231 cells that have normal levels of HER2 expression. DNA was prepared from each of these cell lines using the QIAamp DNA Mini kit (Qiagen, www.qiagen.com) according to the protocol for cultured cells. Each DNA sample was tested by MLPA 20 times and the mean and standard deviation of the results were calculated.
RESULTS
Tumors
The 208 cases included in-house and referred cases; these comprised 193 primary resection specimens and 15 core biopsy samples. The grade of the tumor was specified in 189 cases. The tumor had been assigned to grade 1 in 28.5% cases, to grade 2 in 48.1%, and grade 3 in 23.3% of cases. The tumor were classified as ductal in 75.5% of cases, lobular in 12.5%, mixed ductal and lobular in 2.9%, mucinous in 3.4%, tubular in 2.4%, other subtype (metaplastic, neuroendocrine, or papillary) in 1.9% cases, and a metastatic deposit of breast cancer in 1.4% of cases. FIGURE 1. Macrodissection for enriching invasive breast cancer tissue. A, An area, rich in invasive tumour was marked on the H&E stained section by the pathologist. B, One10 micron de-waxed unstained section is prepared and the marked area is scraped with a pipette tip. This material is then used for DNA extraction with a commercially available kit.
ISH Results
No signal was detectable by CISH in 15 of the 208 cases. These and cases with CISH results in the equivocal range were assessed with FISH. In addition, a proportion of cases, mostly with CISH results in the polysomic range, were also assessed with FISH. Overall, FISH was carried out in 46 cases. FISH failed to produce any signal in 2 cases. In another case there was insufficient tissue for a definitive result. This was a core biopsy with a CISH HER2 copy number of 5.0 (equivocal). FISH was carried out by the central laboratory, but there was insufficient tissue for assessment. In-house FISH was attempted subsequently on a spare slide. Definitive assessment was not possible, but a few cells could be assessed and some showed low-level amplification. As the final status of this case was not be established by ISH owing to insufficient tissue, this case had to be excluded from the final analysis.
At the conclusion of all ISH testing, inclusive of CISH and FISH, 26 cases (12.5%) were classified as amplified and 182 cases (87.5%) as nonamplified, with 1 case as indeterminate owing to insufficient tissue.
MLPA Results
The macrodissection procedure was effective. The pathologist selected and marked the suitable area for MLPA on the H&E section as part of the assessment of the ISH results. This step added a small time increment to the assessment process. The technical scientific staff successfully transferred the markings to the unstained sections, procuring informative tissue samples. Using this approach, DNA suitable for MLPA analysis was successfully extracted from a single 10-mm section of FFPE tissue for all 208 samples, including the 15 samples that were from core biopsy.
Sensitivity and Linearity of MLPA
To determine the appropriate cutoff for the MLPA assay, DNA from the cell line MDA-MB-231, which is known to have normal levels of expression of HER2, was tested 20 times. As shown in Table 2 , the range of values for each of the HER2 probes was determined and the mean and standard deviation was calculated for each probe. Using these values, the cutoff for positive results was set at 4.0 copies for all probes.
Reproducibility
The reproducibility of the MLPA assay was assessed using DNA extracted from the cell line SKBR3, which is known to be HER2-amplified. After testing the DNA 20 times, the mean based on the results from all 3 probes was 8.34 copies (range: 5.73 to 14.64). The mean for individual probes showed some variation, most likely owing to the variation in the binding properties of each of the 3 HER2 probes [probe 1: 8.77 copies (range: 6.80 to 12.32), probe 2: 8.16 (range: 5.73 to 14.64), and probe 3: 8.09 (range: 6.85 to 9.72)]. To compensate for the unequal binding of the probes, we used 2 approaches to classify a sample as amplified, although in practice both methods gave equivalent results. One approach was with regard to a sample as amplified if 2 of the 3 probes were positive. The alternative method of using the mean value of the 3 probes for each sample to determine amplification was also used. The 2 methods gave similar results. In testing unknown samples, 20 of the 23 amplified cases showed amplification of all 3 probes, whereas 3 cases showed amplification in only 2 of 3 probes. In each of these cases it was probe 3 that did not show amplification. This is consistent with the findings of others. 16 The alternative method of using the mean values for the 3 probes did not change the classification category of any of the samples (data not shown).
MLPA analysis produced informative results in all cases. Representative results for MLPA testing of HER2 amplification are shown in Figure 2 . Considering the 207 cases with informative ISH results, the MPLA results were classified as not amplified in 184 cases (88.9%) and amplified in 23 cases (11.1%).
Concordance Between MLPA and ISH
The correlation between ISH and MLPA is shown in Table 3 . All cases classified as amplified by MLPA were also classified as amplified by ISH. Two of 184 cases (1.1%) that were classified as not amplified by MLPA were classified as amplified by ISH.
As shown in Table 4 , using ISH as the reference test, the sensitivity of MLPA is 92%, its specificity 100%, positive predictive value 100%, negative predictive value 98.9%, and overall accuracy 99%.
DISCUSSION
MLPA has been widely used for the assessment of gene copy number in genetic diseases for many years, and has recently been introduced for the assessment of HER2 amplification. It can measure the copy number of up to 45 different gene sequences simultaneously, thus allowing the inclusion of multiple probes for the region of interest and a broad range of controls on multiple chromosomes. The requirement for only short DNA fragments renders this technique applicable to FFPE tissue. Earlier studies have reported a range of broadly concordant results when comparing MLPA with IHC, FISH, and CISH. [12] [13] [14] However, these studies were based on whole tissue sections. Some of these reports have found the sensitivity of the technique too low for clinical application, Mean and standard deviations were calculated and the cutoff for positive results was set at 4.0 copies for all probes.
MLPA indicates multiplex ligation-dependent probe amplification.
particularly for cases with a low percentage of invasive tumor and low levels of amplification. Laser dissection, although capable of producing the most homogenous samples, is too time-consuming for routine clinical use. One recent report has used both laser dissection and H&E-guided manual microdissection with a scalpel, similar to our approach in this study. 16 In targeting cases with a low tumor content ( <60%) and cases with discrepant MLPA and ISH results, Moelans et al 16 found that both tumor enrichment methods improved the sensitivity of MLPA. Although both techniques led to an increase in the HER2 copy number as measured by MLPA, the differences between the 2 techniques were not significant, leading the investigators to conclude that laser microdissection was unnecessary in all but selected cases with a very small proportion of invasive tumor. These findings support the methods used in this study, which is also a clinically more feasible approach. The demonstration of a 99% level of concordance between ISH and MLPA results for determining HER2 status of breast cancers samples is encouraging. The advantages of MLPA are that it offers the capacity for high throughput; the results are available within 48 hours; the reagents are stable fluids, simplifying quality assurance processes; and the cost of the reagents is significantly lower than that of other assays. The technique requires a thermal cycler, which is now readily available in most pathology laboratories, and access to a DNA sequencer. Furthermore, as the technique requires as little as 20 ng of DNA, the partially fragmented DNA that is usually extracted after formalin fixation of tissue is still suitable for MLPA. In practice, the modest tissue requirements for MLPA were satisfied with the provision of one 10-mm tissue section and informative results were provided in all cases, including core biopsies. It is also worth emphasizing that the samples were from in-house and referred cases, with a range of fixation and processing protocols. The robustness of MLPA to fixation and processing variation contrasts favorably with the fragility of ISHbased and IHC-based assays.
One usual impediment to the use of PCR-based tests is that the test is often not targeted to specific areas of the sample, as normal tissue, DCIS, and invasive cancer are all included in the samples. Our approach of delineating the invasive tumor on the histologic slide ensures the samples are highly enriched for the region of interest. This approach, in combination with the modest tissue requirements of MLPA, extends the utility of the technique to cases in which the invasive cancer is a small part of a larger field of DCIS or when the assessment is carried out on core biopsies. Using macrodissection, the pathologist can select the invasive carcinoma, ensuring that the assay is directed to the invasive component of the lesion.
The MLPA process can assess copy number changes in as many as 45 genomic sequences in 1 assay. This facility has several advantages. First, the kit includes 3 separate probes for the HER2 gene, improving the sensitivity of the assay. There are also 25 other DNA segments being used as controls. These include genes that are not usually altered significantly in breast cancer. The capacity to assess up to 45 DNA segments simultaneously means that in addition to the 3 HER2 gene sequences, DNA sequences belonging to several other genes both upstream and downstream of the HER2 gene can be assessed in the same reaction. This information is of potential interest, as it may provide further data to assist in the prediction of response to systemic therapy in tumors that are HER2-amplified.
Whereas ISH-based and IHC-based assays produce only semiquantitative results, a further distinguishing feature of MLPA is that it is a quantitative technique. This affords the possibility in future studies to assess the level of patient response to targeted therapy according to the level of gene amplification as a continuous variable, thereby determining clinically significant thresholds for HER2 copy number.
Applications of MLPA
If our results are confirmed by others and with larger datasets, MLPA may potentially be used in the determination of the HER2 status of all newly diagnosed breast cancers. An argument can be made for the rapid identification of amplified cases using MLPA, as all cases classified as such in this study were confirmed by ISH. Cases with nonamplified MLPA results can then be assessed further with IHC and ISH tests, to identify the small percentage of cases from among them (1.1% in this study) that are HER2-amplified.
Apart from its potential as a testing platform for general application, MLPA has applications in specific situations. These include the work-up of cases with discordant IHC and ISH results, cases with equivocal HER2 test results, and in the determination and significance of polysomy.
Cases With Discordant IHC and ISH Results
It is estimated that in approximately 4% of cases the results of ISH and IHC are discordant. 2 These include cases with either IHC3+ and negative ISH results, or IHC results other than 3+, but positive ISH results. Clinical outcome data are not available specifically for the group with discordant results. MLPA would provide an additional testing assay to enable determination of the HER2 status of these ambiguous cases.
Equivocal HER2 Test Results
The availability of an additional platform for HER2 testing will be particularly advantageous in the assessment of the estimated 3% of cases in which ISH results are equivocal. 2 At present, the CAP/ASCO guidelines define the equivocal range for ISH assays as HER2/ CEP17 ratio between 1.8 and 2.2, or average gene copy numbers of between 4.0 and 6.0 HER2 genes per nucleus for test systems without an internal control probe. The ASCO/CAP recommendations for the work-up of these equivocal ISH samples are to count additional fields or repeat the ISH assay. If, despite these efforts, the ISH result remains equivocal, IHC is recommended to determine protein expression for the sample. However, in many laboratories IHC is the first-line test and equivocal IHC results (2+) are likely to have occasioned ISH testing in the first place. Access to a completely separate, independent testing assay, such as MLPA, would be particularly valuable in these cases.
Determination of the Significance of Polysomy
The area of polysomy is another potential discussion to which the MLPA technique may contribute. This group is estimated to comprise 8% of all cases. 2 As noted in the ASCO review, there is no accepted definition of what constitutes polysomy, as different criteria have been used to define this category. Most of these cases have between 4 and 6 copies of the HER2 gene. If polysomy 17 is defined as 3 or more copies of CEP17, most of these cases are not associated with protein or mRNA overexpression. This has also been observed in tumors with a HER2 gene copy number of between 4 and 6. As sequences being tested in the MLPA assay include genes throughout chromosome 17, MLPA data would shed additional light onto the nature and significance of polysomy. Of note is the fact that a new kit is now available commercially that includes a centromeric probe for chromosome 17, facilitating further studies in the near future.
CONCLUSIONS
The 99% concordance between MLPA and ISH results satisfies the CAP/ASCO guidelines for validation of a test for HER2 testing. The results merit consideration of the MLPA assay as an additional platform for HER2 testing. The low cost, high throughput, robustness, and rapid turnaround time of MLPA have tremendous value in the current era of mandatory HER2 testing of all newly diagnosed breast cancers.
